ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 1715 • ACR Convergence 2020

    Longitudinal Patterns of Remission in Real-World Early Rheumatoid Arthritis Patients: Results from the Canadian Early Arthritis Cohort (CATCH)

    Orit Schieir1, Glen Hazlewood2, Susan Bartlett3, Marie-France Valois3, Louis Bessette4, Gilles Boire5, Carol Hitchon6, Edward Keystone7, Janet Pope8, Carter Thorne9, Diane Tin9, Vivian Bykerk10 and Canadian Early Arthritis Cohort (CATCH) Investigators11, 1Canadian Early Arthritis Cohort Study, Montreal, Canada, 2University of Calgary, Calgary, AB, Canada, 3McGill University, Montreal, Canada, 4Laval University, Quebec, Canada, 5Universite de Sherbrooke, Sherbrooke, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, 8Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10Hospital for Special Surgery, New York, NY, 11Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

    Background/Purpose: Early diagnosis and rapid initiation of DMARDs following a treat-to-target approach have made remission a realizable goal for many persons living with RA. Despite…
  • Abstract Number: 0321 • ACR Convergence 2020

    Outcome Measures in Psoriatic Arthritis Registries Are Very Heterogeneous: A Systematic Literature Review of 27 Registries, or 16183 Patients

    Krystel Aouad1, Georgia Moysidou1, Antsa Rakotozafiarison1, Bruno Fautrel2 and Laure Gossec1, 1Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, 2Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France

    Background/Purpose: Psoriatic arthritis (PsA) is a multidimensional inflammatory disease for which multiple outcome measures can be used, to assess disease activity e.g. through composite scores,…
  • Abstract Number: 0884 • ACR Convergence 2020

    Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Patrick Zueger4 and Alexis Ogdie5, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…
  • Abstract Number: 1962 • ACR Convergence 2020

    Utilization of Telehealth Among Patients with Rheumatic Diseases in the Early Months of the COVID-19 Pandemic

    Kristin Wipfler1, Yomei Shaw2, Teresa Simon3, Adam Cornish1, Patricia Katz4 and Kaleb Michaud5, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2FORWARD, The National Databank for Rheumatic Diseases, East Lansing, MI, 3Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, 4University of California, San Francisco, Novato, CA, 5University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Many health care providers replaced in-person clinical visits with telehealth visits or expanded their telehealth offerings due to the COVID-19 pandemic. We sought to…
  • Abstract Number: 0390 • ACR Convergence 2020

    Baseline Characteristics of Systemic Sclerosis (SSc) Patients with Restrictive Lung Disease in a Multi-Center United States Based Longitudinal Registry

    Flavia Castelino1, John VanBuren2, Emily Startup2, Shervin Assassi3, Elana Bernstein4, Lorinda Chung5, Chase Correia6, Luke Evnin7, Tracy Frech8, Jessica Gordon9, Faye Hant10, Laura Hummers11, Dinesh Khanna12, Nora Sandorfi13, Ami Shah14, Victoria Shanmugam15 and Virginia Steen16, 1Massachusetts General Hospital/Harvard Medical School, Boston, MA, 2University of Utah, Salt Lake City, UT, 3University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, 4Columbia University, New York, NY, 5Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, 6Northwestern University, Chicago, IL, 7Scleroderma Research Foundation, Brisbane, CA, 8University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, 9Hospital for Special Surgery, New York, NY, 10Medical University of South Carolina, Charleston, SC, 11Johns Hopkins Univerisity, Ellicott City, MD, 12University of Michigan, Ann Arbor, MI, 13University of Pennsylvania, Philadelphia, PA, 14Johns Hopkins University School of Medicine, Ellicott City, MD, 15The George Washington University, Washington, DC, 16Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in SSc. Several international observational studies have evaluated characteristics of ILD in their SSc patient…
  • Abstract Number: 1009 • ACR Convergence 2020

    Missing Data and Multiple Imputation in Rheumatoid Arthritis Registries Using Sequential Random Forest Method

    Ahmed Al-Saber1, Adeeba Al-Herz2, Jiazhu Pan1, Khulood Saleh3, Adel Al-Awadhi4, Waleed Al-Kandari3, Eman Hasan5, Aqeel Ghanem6, Mohammed Hussain5, Yaser Ali7, Ebrahim Nahar7, Ahmad Alenizi8, Sawsan Hayat7, Fatemah Abutiban9, Ali Aldei5, Amjad Alkadi10, Heba Alhajeri7, Husain Behbehani3, Naser Alhadhood3, Khaled Mokaddem5, Ahmed Khadrawy3, Ammad Fazal3, Agaz Zaman7, Ghada Mazloum7, Youssef Bartella5, Sally Hamed5 and Ramia Alsouk8, 1Department of Mathematics and Statistics, University of Strathclyde, Glasgow, United Kingdom, 2Al-Amiri Hospital, Kuwait City, Kuwait, 3Farwania Hosiptal, Farwania, Kuwait, 4Faculty of Medicine, Kuwait University, Jabria, Kuwait, 5Al-Amiri Hospital, Kuwait, Kuwait, 6Mubarak Al-Kabeer Hospital, Kuwait City, Kuwait, 7Mubarak Al-Kabeer Hospital, Hawally, Kuwait, 8Jahra Hospital, Jahra, Kuwait, 9Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah hospital, State of Kuwait, Jahra, Kuwait, 10Sabah Hospital, Kuwait, Kuwait

    Background/Purpose: Missing data in clinical epidemiological researches violate the intention to treat principle, reduce statistical power and can induce bias if they are related to…
  • Abstract Number: 1978 • ACR Convergence 2020

    Prevalence and Factors Associated with Patient-Physician Discordance Among RA Patients Initiating Advanced Therapy

    Jeffrey Curtis1, Rose Medeiros2, I-Heng Lee3, Rachel Mackey4, Richard Haubrich3, Hao Hu5, Jeffrey Greenberg6 and Alicea Wu3, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Corrona, LLC, Waltham, MA, 3Gilead Sciences, Foster City, CA, 4Corrona, LLC and University of Pittsburgh, Waltham, MA, 5Gilead Sciences, Inc., Foster City, CA, 6Corrona, LLC and NYU School of Medicine, Waltham, MA

    Background/Purpose: Some rheumatoid arthritis (RA) patients rate their disease activity worse than their physician does, but recent prevalence and factors associated with such discordance have…
  • Abstract Number: 0454 • ACR Convergence 2020

    Anticytokine Therapies for Inflammatory Rheumatic Disease (IRD) Are Associated with Reduced Hospitalisation Following Community COVID-19 Infection; Results of the Trinity Rheumatology and Covid-19 Registry – TRACR

    Rachael Flood1, Richard Conway2, David Kane1 and Ronan Mullan1, 1Tallaght University Hospital, Dublin, Ireland, 2St James's Hospital, Dublin, Ireland

    Background/Purpose: Anticytokine biological disease modifying anti-rheumatic drugs (bDMARD), which are widely prescribed  for Inflammatory Rheumatological Diseases (IRD) are currently undergoing clinical trials for the treatment…
  • Abstract Number: 1029 • ACR Convergence 2020

    Clinical Characteristics of Patients with Axial Spondyloarthritis in China: Results from the ChinaAS Registry

    Jinmei Su1, Runsheng Wang2, Ping Zhu3, Yanhong Wang4, Shangzhu Zhang1, Linyi Peng1, Min Yang5, Ling Lei6, Li Qin7, Mengtao Li8 and Xiaofeng Zeng8, 1Peking Union Medical College Hospital, Department of Rheumatology, Beijing, China (People's Republic), 2Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 3Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), 4Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China (People's Republic), 5Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (People's Republic), 6Department of Rheumatology and Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), 7Department of Rheumatology, The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), 8Peking Union Medical College Hospital, Department of Rheumatology, Beijing, Beijing, China (People's Republic)

    Background/Purpose: The ChinaAS is a nationwide, multicenter registry of patients with axial spondyloarthritis (SpA) in China to facilitate research in epidemiology, pathogenesis, diagnosis and treatment…
  • Abstract Number: 0601 • ACR Convergence 2020

    The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases

    Kent Kwas Huston1, Simon Helfgott2, Scott Milligan3, Jasvinder Singh4, Nehad Soloman5, Brandon Weil3 and Colin Edgerton6, 1Kansas City Physician Partners, Kansas City, MO, 2BWH- HMS, Boston, MA, 3Trio Health, Louisville, CO, 4University of Alabama at Birmingham, Birmingham, AL, 5Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, 6Articularis Healthcare, Summerville, SC

    Background/Purpose: Persistence on therapy is an important consideration in rheumatic diseases. There are multiple treatment options that influence long term disease management and a better…
  • Abstract Number: 1142 • ACR Convergence 2020

    Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution

    Rebecca Overbury1, Tracy Frech2, John Bohnsack3, CJ Inman1, Sara Stern1, Karen James1, Erin Treemarcki4 and Aimee Hersh4, 1University of Utah and Primary Children's Hospital, Salt Lake City, UT, 2University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, 3University of Utah and Primary Children's Hospital, Cincinnati, OH, 4University of Utah and Primary Children's Hospital, Salt Lake City

    Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…
  • Abstract Number: 0714 • ACR Convergence 2020

    Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry

    Daniel J Lovell1, Nikolay Tzaribachev2, Esi Morgan3, Gabriele Simonini4, Thomas Griffin5, Ekaterina Alexeeva6, John Bohnsack7, Andrew Zeft8, Gerd Horneff9, Richard Vehe10, Valda Stanevicha11, Stacey Tarvin12, Maria Trachana13, Adam Huber14, Daniel Kietz15, Ilonka Orban16, Jason Dare17, Ivan Foeldvari18, Pierre Quartier19, Alyssa Dominique20, Tzuyung Douglas Kou20, Robert Wong20, Alberto Martini21, Hermine Brunner3 and Nicolino Ruperto22, 1PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Anna Meyer Children's Hospital, Firenze, Italy, 5Levine Children's Hospital, Charlotte, NC, 6Scientific Center of Children’s Health of RAMS, Moscow, Russia, 7University of Utah and Primary Children's Hospital, Cincinnati, OH, 8Cleveland Clinic, Cleveland, OH, 9Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 10University of Minnesota, Minneapolis, MN, 11Riga Stradins University, Riga, Latvia, 12Riley Children’s Health, Indianapolis, IN, 13Aristotle University of Thessaloniki, Thessaloníki, Greece, 14Dalhousie University, Halifax, NS, Canada, 15Children’s Hospital of Pittsburgh, Pittsburgh, PA, 16National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 17University of Arkansas for Medical Sciences, Little Rock, AR, 18Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, 19Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 20Bristol-Myers Squibb Company, Princeton, NJ, 21PRINTO, Istituto Giannina Gaslini, Genova, Italy, 22Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
  • Abstract Number: 1153 • ACR Convergence 2020

    Trends in Timing of Biologic Use for Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry

    Ginger Janow1, Timothy Beukelman2, Yukiko Kimura3, Rayfel Schneider4, Shalini Mohan5, Gail Rodich6 and Mary Beth Son7, 1Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ, 2University of Alabama at Birmingham, Birmingham, AL, 3Hackensack Meridian School of Medicine, Hackensack, NJ, 4University of Toronto, The Hospital for Sick Children, Toronto, Canada, 5Genentech, Inc., South San Francisco, CA, 6Genentech, Mill Valley, CA, 7Boston Children's Hospital, Boston, MA

    Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes.  There may…
  • Abstract Number: 0716 • ACR Convergence 2020

    Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study

    Ruud Verstegen1, Peter Shrader2, Stephen Balevic3, Timothy Beukelman4, Colleen Correll5, Anne Dennos6, Thomas Phillips2 and Brian Feldman1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2Duke University, Durham, 3Duke University Medical Center, Durham, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Minnesota, Minneapolis, MN, 6Duke University, Durham, NC

    Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…
  • Abstract Number: 1155 • ACR Convergence 2020

    Long-term Safety Profile of Anakinra in Patients with Systemic Juvenile Idiopathic Arthritis

    Gabriella Giancane1, Riccardo Papa1, Sebastiaan Vastert2, Francesca Bagnasco1, Joost Swart1, Pierre Quartier3, Jordi Anton4, Isabelle Kone Paut1, Sylvia Kamphuis1, Troels Herlin5, Helga Sanner1, Fabrizio De Benedetti6, Elena Tsitsami7, Susan Mary Nielsen1, Estefania Moreno1, Chiara Pallotti1, Karin Franck-Larsson8, Håkan Malmström8, Susanna Cederholm9, Nico Wulffraat1 and Nicolino Ruperto10, 1IRCCS Istituto Giannina Gaslini, PRINTO, Genoa, Italy, Genova, Italy, 2University Medical Center Utrecht, Utrecht, Netherlands, 3Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 4Sant Joan de Déu Hospital, Madrid, Spain, 5Aarhus University Hospital, Aarhus, Denmark, 6Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 7Aghia Sophia Childrens Hospital, Athens, Greece, 8Swedish Orphan Biovitrum, Stockholm, Sweden, 9Sobi, Stockholm, Sweden, 10PRINTO, Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: To evaluate the long-term safety profile of anakinra in patients with systemic juvenile idiopathic arthritis (sJIA)Methods: Data from patients with sJIA according to the…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology